Circular RNA profiling identified as a biomarker for predicting the efficacy of Gefitinib therapy for non-small cell lung cancer

Abstract excerpt

BACKGROUND: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have become important treatment options for non-small cell lung cancer (NSCLC) patients with EGFR sensitive mutation. However, the detection of EGFR driver mutation is impeded by the lack of adequate tumor tissues, histopathological type, long detection period, and the heterogeneity of a tumor. Therefore, it is necessary to...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Biomarkers in Disease Mechanisms
• Share to Circular RNAs in diseases
• Share to Lung Cancer Treatments and Mutations